The in vivo results of QPI-1007 mark a new era for Quark. We can
now rely solely on internally-developed novel compositions and proprietary
siRNA structures to develop products that have the potential to provide
greater efficacy than current treatments. The breadth of our new structures
allows us to selectively pick the most efficacious, stable siRNA structure,
which is the most suitable for the specific sequence."
Dr. Logan stated, "QPI-1007 displayed significant neuroprotective
activity compared to untreated controls and two different control siRNA
molecules in our in vivo model. These results are very exiting. They show
that QPI-1007 is a promising drug for ocular neuroprotection."
Dr. Di Polo commented, "The characteristic visual field changes and
loss of vision in glaucoma are caused by the selective degeneration of
retinal ganglion cells. Our results suggest that QPI-1007 may be an
effective neuroprotective therapy for retinal ganglion cells in acute
injuries such as non-artheritic ischemic optic neuropathy, and also in
slow-progressing chronic optic nerve injuries such as glaucoma. QPI-1007
has the potential to serve an unmet medical need for these indications."
About Quark Pharmaceuticals, Inc.
Quark Pharmaceuticals, Inc. is a development-stage pharmaceutical
company engaged in discovering and developing novel therapeutic RNAi drug
candidates. Quark has a fully integrated drug development platform that
spans therapeutic target identification to drug development. Quark's RNAi
technology includes novel siRNA structures and chemistry providing Quark
with freedom to operate in the siRNA intellectual property arena, as well
as the ability to deliver siRNA non invasively to target tissues including
the eye, ear, kidney, lung, spinal cord and brain.
PF-4523655 (RTP801i-14), currently in Phase II clinical trials, is a
synthetic, chemically modified, siRNA molecule to inhibit the expression of
the gene RTP801, licensed to Pfizer. In
'/>"/>
SOURCE Quark Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 Related medicine technology :1.
Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)2.
Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss3.
Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules4.
Quark Pharmaceuticals Appoints New Chief Medical Officer5.
Quark Pharmaceuticals Signs Collaboration Agreement With University of Michigan for Development of Proprietary SiRNA Compounds for Noise-Induced Hearing Loss6.
Quark Pharmaceuticals, Inc. Announces First Systemic siRNA Dosing in Humans7.
Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema8.
Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial9.
Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)10.
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML11.
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia